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The free b-subunit of human chorionic gonadotropin b is expressed in several nontrophoblastic tumours and this is usually
associated with aggressive disease. Little is known about human chorionic gonadotropin b expression in renal cancer. We
determined the pretreatment levels of human chorionic gonadotropin b in serum of patients with renal cell carcinoma, and studied
whether elevated levels predicted the clinical outcome. Serum samples were collected before surgery from 177 patients with renal
cell carcinoma and from 84 apparently healthy controls. Human chorionic gonadotropin b in serum was measured by a highly
sensitive time-resolved immunoﬂuorometric assay. The prognostic value of human chorionic gonadotropin b, and of usual clinical
and pathological variables was analyzed by the Kaplan-Meier method, the log rank test and Cox multiple hazard regression. The
serum concentrations of human chorionic gonadotropin b were increased in 23% of the renal cell carcinoma patients and they
were signiﬁcantly higher in patients with renal cell carcinoma than in controls (P50.0001). The concentrations did not correlate
with clinical stage and histopathological grade, but patients with increased human chorionic gonadotropin b levels had signiﬁcantly
shorter survival time than those with levels below the median (cut-off 1.2 pmol l
71, P=0.0029). In multivariate analysis human
chorionic gonadotropin b, tumour stage and grade were independent prognostic variables. The serum concentration of human
chorionic gonadotropin b is an independent prognostic variable in renal cell carcinoma. The preoperative value of human chorionic
gonadotropin b in serum may be used to identify patents with increased risk of progressive disease.
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The incidence of urological malignancies such as prostate cancer,
bladder cancer and kidney cancer has been steadily increasing in
the Western world during the past decades (Parkin et al, 1999).
Renal cell carcinoma (RCC) arising in the renal parenchyma is
the most common malignancy of the kidney. Conventional renal
cell carcinoma (CRCC) and papillary renal cell carcinoma account
for 85–90% of the ﬁve distinct types of RCCs. The fairly indolent
chromophobe renal cell carcinoma and the unclassiﬁed category
account for approximately 5% each, while the rarest and most
aggressive type is collecting duct carcinoma (Kovacs et al, 1997).
Clinical stage and nuclear grade are the most important prognostic
factors in RCC (Fuhrman et al, 1982), but within a given disease
stage the outcome is highly variable, and other prognostic indicators
are needed to identify patients with high risk of progressive disease
(Golimbu et al, 1986). Cell proliferation markers, p53 mutations,
growth factor expression, and intratumoural microvessel density
have been investigated as prognostic indicators, with partly contra-
dicting results (Gelb et al, 1997; Grignon et al, 1995). Among the
serum markers studied, VEGF, interleukin-10, CA-125, and
tumour-associated trypsin inhibitor (TATI) have been shown a
prognostic value, but no speciﬁc markers are available (Grankvist
et al, 1997; Jacobsen et al, 2000; Paju et al, 2001; Wittke et al, 1999).
Human chorionic gonadotropin (hCG) is a 38 kDa glycoprotein
hormone consisting of two dissimilar subunits, a and b (hCGa and
hCGb) (Bahl et al, 1972). HCG is normally produced by tropho-
blasts during pregnancy and it is a very sensitive marker for
trophoblastic tumours (Vaitukaitis and Ebersole, 1976). Expression
of hCGb is a fairly common phenomenon in several non-tropho-
blastic tumours (Alfthan et al, 1992a; Marcillac et al, 1992), and
in transitional cell carcinoma of the bladder (Iles et al, 1989)
and several other tumours this is associated with aggressive and
therapy resistant disease. Tissue expression of hCGb seems to have
prognostic signiﬁcance in carcinomas of the prostate (Sheaff et al,
1996), and hCGb in serum has been found to be of prognostic
value in ovarian cancer (Ind et al, 1997). The aim of this study
was to evaluate the prognostic value of hCGb in sera of patients
with RCC in relation to established prognostic factors.
MATERIALS AND METHODS
Patients
Data for this retrospective analysis was collected from 177 patients
with RCC from whom pretreatment serum samples were available.
The patients underwent radical nephrectomy at the University
Hospital of Umea ˚, Sweden between 1983 and 1995. The study
included 111 men and 66 women with a mean age of 65 years
(range 25–85) (Table 1). Informed consent was obtained from
all patients included in the study. Serum samples were collected
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www.bjcancer.combefore surgery and stored at 7808C until analysis. Staging proce-
dures included physical examination, chest radiography,
ultrasonography and computer tomography. Patients with skeletal
symptoms or elevated serum alkaline phosphatase were assessed
by bone scintigraphy and skeletal radiography. After nephrectomy,
all patients were followed up with clinical and radiological exami-
nations. At the last follow-up, 47 of 177 patients were alive with a
median follow-up time of 124 months, (range 34–191 months).
Among 130 patients that had died, 95 had died of RCC and 35
of other causes (Table 1). Sera from 84 apparently healthy volun-
teers was used as a reference group.
Tumour staging
Tumour staging was performed according to 1997 TNM Stage clas-
siﬁcation (Sobin and Wittekind, 1997). Among the 177 patients, 70
patients had TNM stage I and II (pT1–pT2, N0, M0), 54 stage III
(pT1–T3a–c, N0–N1, M0) and 53 were of stage IV (pT1–T4,
N0–N3, M1). Nuclear grading was performed according to Skin-
ner et al (1971) and DNA ploidy according to Ljungberg et al
(1996).
Serum determinations
HCGb in serum was determined by a time-resolved immuno-
ﬂuorometric assay as earlier described (Alfthan et al, 1988). With
a sample volume of 25 ml in a total assay volume of 225 ml the
detection limit was 0.45 pmol l
71. The upper reference limit of
the assay for hCGb in serum was 2 pmol l
71. The reference range
is identical in women and men and it is not dependent on age.
Serum creatinine was measured by a routine method in the
Laboratory of Clinical Chemistry, University Hospital, Umea ˚,
Sweden. The upper reference limit was 125 mmol l
71.
Statistical analysis
Differences in serum hCGb concentrations in patients with various
stages and grades and controls were analyzed by the Mann-Whit-
ney U-test. Survival curves were plotted using the Kaplan-Meier
method, and comparison of survival times was performed with
the log-rank test. Serum hCGb was also studied as a categorical
variable using quartiles (hCGb 50.8 pmol l
71, 0.8–1.2 pmol l
71,
1.2–1.95 pmol l
71 and hCGb 41.95 pmol l
71). The indepen-
dence of hCGb as a predictor of survival was analyzed by
multivariate analysis using the Cox proportional hazard model with
serum hCGb, nuclear grade and stage as input variables. The statis-
tical endpoint was survival measured from the date of nephrectomy
to date of death or date of last follow-up. Cases of death from
unrelated causes were censored. All tests were two-sided and P-
values below 0.05 were considered signiﬁcant.
RESULTS
The median concentration of creatinine in serum of RCC patients
was 86 mmol l
71 (range 45–353 mmol l
71), and elevated levels
occurred in 13%. The serum concentrations of hCGb were not
related to serum creatinine.
The concentration of hCGb in serum was elevated
(42 pmol l
71) in 23% of the patients with RCC (Table 2) and
20 of these (11%) had values 44 pmol l
71. The median concen-
tration of hCGb in serum was 1.2 pmol l
71 (range 0.2–
18 pmol l
71), which was signiﬁcantly higher (P50.0001) than in
controls (median 0.4 pmol l
71, range 0.2–1.3 pmol l
71). There
was no difference in hCGb levels between males and females,
different age groups, different RCC types, aneuploid and diploid
tumours, or tumours with and without venous invasion. Serum
hCGb concentrations were not either signiﬁcantly correlated with
tumour stage or grade (Figure 1).
Clinical stage and grade were highly predictive of disease speciﬁc
survival (P50.0001 each) in univariate analysis. Patients with
serum hCGb concentrations above the median value
(1.2 pmol l
71) had signiﬁcantly shorter survival than those with
lower levels (P=0.0029) (Figure 2A). A difference in survival time
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Table 1 Patient and tumour characteristics
Characteristics No of cases
Mean age, years (range): 64.5 (25–85)
Sex 111/66
Clinical outcome: alive/dead of RCC/dead of other cause 47/95/35
Tumour stage, follow-up status: alive/dead of RCC/dead of other cause
I 22/3/19
II 15/5/6
III 7/38/9
IV 3/49/1
Tumour grade
10
23 9
39 1
44 7
RCC type
Conventional 140
Papillary 23
Chromophobe 10
Unclassiﬁed 4
Venous invasion: no invasion/tumour thrombus 117/60
Table 2 Fraction of elevated serum hCGb concentration in relation to
stage
Tumour stage Elevated serum hCGb* (%)
I 8/47 (17)
II 5/23 (22)
III 12/54 (22)
IV 16/53 (30)
All 41/177 (23)
*Cut-off, hCGb 2 pmol l
71.
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Figure 1 The distribution of hCGb serum concentrations in controls and
patients with various stages of RCC. The dashed line indicates the upper
reference limit.
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IV, Figure 2C) (P=0.06). When serum hCGb concentration was
compared as quartiles there was no difference in disease speciﬁc
survival between the two lowest quartiles or between quartiles 3
and 4 (P40.6). In multivariate analysis using the Cox regression
model with age, gender, serum hCGb, nuclear grade and stage as
input variables, stage, grade and serum hCGb concentration were
independently associated with the disease speciﬁc survival (Table
3).
DISCUSSION
RCC is known for its unpredictable clinical behaviour. Recurrence
can occur many years after surgery and metastases can sponta-
neously regress after removal of the primary tumour. In addition
to clinical stage and grade, DNA ploidy has been found to be a
prognostic factor (Ljungberg et al, 1996), but a marker available
prior to surgery could be used to optimize treatment. Of the many
serum markers studied, only a few, i.e. VEGF, interleukin-10, CA-
125, and TATI are of potential prognostic value (Grankvist et al,
1997; Jacobsen et al, 2000; Paju et al, 2001; Wittke et al, 1999).
Clinical parameters such as performance status, serum lactate dehy-
drogenase, hemoglobin, serum calcium and prior nephrectomy
have also been used to predict survival of patients with metastatic
RCC (Motzer et al, 1999).
HCG immunoreactivity occurs in many different molecular forms
in serum and urine. During pregnancy, intact hCG is the main form
in serum and the proportion of hCGb is 1–8%. Various forms of
hCG can also be detected in serum of non-pregnant women and
men by highly sensitive methods. The concentrations of hCG in
serum and hCG and hCGb in urine increase with age, whereas those
of hCGb in serum are similar in men and women and change very
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Figure 2 Kaplan Meier cancer speciﬁc survival according to preoperative serum hCGb concentration in patients with RCC. Results for patients with
tumours of all stages (A), stages I-III (B) and stage IV (C). The median value of the patients (1.2 pmol l
71) was used as a cut off.
Table 3 Factors independently associated with decreased cumulative
survival
Regression coefﬁcient RR
(b) P (95% conﬁdence interval)
Grade 1.15 =0.032 3.2 (1.1–9.0)
Stage 2.34 50.0001 10.3 (4.8–22.3)
hCGb 0.48 =0.022 1.6 (1.1–2.5)
RR=relative risk.
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(2), 185–189little with age (Alfthan et al, 1992b). In addition to being a sensitive
marker for trophoblastic tumours of placental or gonadal origin,
hCGb is also expressed by many non-trophoblastic tumours includ-
ing ovarian, gastrointestinal and squamous cell carcinomas. Contrary
to trophoblastic tumours, these very seldom express intact hCG. A
very moderate (up to two-fold) increase of hCGb in serum may occur
in patients with benign pancreatic and hepatobiliary diseases, but this
does not invalidate the use of hCGb as a tumour marker (Alfthan et
al, 1992a).
Expression of hCGb has been observed in various tumours and
cell lines on both at the protein and mRNA level (Alfthan et al,
1992a; Iles et al, 1989; Ind et al, 1997; Sheaff et al, 1996), but there
is little data on the expression in renal tumours. Increased concen-
trations of hCGb have been demonstrated by radioimmunoassay in
concentrated urine specimens from RCC patients (Fukutani et al,
1983), but the study included very few cases. The present study
shows that the concentrations of hCGb in serum were elevated
in 23% of the patients, and the median concentrations were signif-
icantly higher than in controls (P50.0001). Patients with serum
hCGb levels above the median value (1.2 pmol l
71) had signiﬁ-
cantly shorter survival than those with lower levels (P50.0029).
In multivariate analysis serum hCGb, tumour stage and grade were
independent prognostic variables. The fairly low frequency (23%)
of elevated serum hCGb suggest that this marker is expressed by
only a part of the RCCs. However, because normal levels between
1.2 and 2 pmol l
71 were associated with adverse prognosis, it is
possible that part of the hCGb in these patients is derived from
the tumour. A possible correlation with the response to treatment
could not be evaluated in this study. The absence of a correlation
with stage indicates that elevated levels are not only a result of
tumour burden, but hCGb expression rather characterizes a
subgroup of tumours. The lack of signiﬁcant correlation with
established prognostic variables such as grade, stage and DNA-ploi-
dy demonstrates the independent character of this marker.
HCGb expression has been regarded as a characteristic of malig-
nant transformation or dedifferentiation of cells, and its association
with aggressive disease in transitional cell carcinoma of the bladder
is well documented (Iles et al, 1989). The association with poor
prognosis in RCC is in line with the results for other tumours. Free
hCGb has no known hormonal activity, but it has been shown to
stimulate phospholipid methylation in rat Leydig cells (Ronco et al,
1993), rendering it a potential biological role. The three dimen-
sional structure of hCGb resembles that of the cysteine knot
growth factors (Lapthorn et al, 1994), and it has a stimulating
effect on the growth of cancer cells in vitro, suggesting paracrine
or autocrine growth factor-like activity. Recently hCGb has been
shown to confer immortality features to cells by inhibiting apopto-
sis (Butler et al, 2000). This is a potential explanation for aggressive
tumour behaviour of hCGb expressing tumours.
The clinical utility of hCGb in the management of RCC is
limited by the infrequent expression. About one fourth of the
patients had elevated levels and in half of these the elevation was
substantial. However, a prognostic value was observed even with
normal levels exceeding the median value, and this was the case
also in patients with advanced disease. Thus it appears worthwhile
to study whether hCGb could be used as an aid in the selection of
therapy or in monitoring of the disease after primary therapy. In
conclusion, our results indicate that hCGb in serum is a prognostic
factor independent of stage and grade that can be used to identify a
subgroup of patients with increased risk of aggressive disease.
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